Synlogic, Inc. Common Stock (SYBX)

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update.

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -54.05% and 2.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 1% on Friday. The Dow traded down 0.09% to 38,691.21 while the NASDAQ rose 1.26% to 15,992.17. The S&P 500 also rose, gaining, 0.55% to 5,025.21. Check This Out: How To Earn $500 A Month From Principal Financial Group Stock Ahead Of Q4 Print   Leading and Lagging Sectors   Information technology shares rose by 1.4% on Friday. In trading on Friday, energy shares fell by 1.2%.   Top Headline   Newell Brands Inc (NASDAQ: NWL) reported upbeat sales for its fourth quarter, but issued a weak forecast. The company reported fourth-quarter revenues of $2.076 billion, beating the analyst consensus of $1.980 billion. Revenues fell 9.1% year over year. Normalized EPS of 22 cents topped the consensus of 17 cents. The company sees FY24 sales decline of 8% to 5%. Newell Brands sees adjusted EPS of 52 cents to 62 cents versus estimates of 77 cents.   Equities Trading UP   Intelligent Bio Solutions ...

Price targets on these stocks are miles above their present market values.

The body's so-called germ squad in the gut can be tweaked, treating diseases including autism and Parkinson's disease.